HROW - Harrow Health, Inc. Stock Price and Quote

HROW [NASD]

Healthcare | Drug Manufacturers - Specialty & Generic | USA

Index	-	P/E	-	EPS (ttm)	-0.83	Insider Own	0.30%	Shs Outstand	27.35M	Perf Week	25.70%
Market Cap	520.14M	Forward P/E	50.21	EPS next Y	0.38	Insider Trans	-	Shs Float	25.25M	Perf Month	32.49%
Income	-22.60M	PEG	-	EPS next Q	-0.12	Inst Own	52.80%	Short Float / Ratio	4.61% / 4.78	Perf Quarter	62.34%
Sales	88.50M	P/S	5.88	EPS this Y	-432.70%	Inst Trans	-5.83%	Short Interest	1.16M	Perf Half Y	176.83%
Book/sh	0.04	P/B	478.25	EPS next Y	156.70%	ROA	-23.00%	Target Price	19.62	Perf Year	142.05%
Cash/sh	1.81	P/C	10.57	EPS next 5Y	15.00%	ROE	-318.40%	52W Range	5.40 - 19.19	Perf YTD	27.91%
Dividend	-	P/FCF	260.07	EPS past 5Y	14.30%	ROI	3.40%	52W High	-1.62%	Beta	0.20
Dividend %	-	Quick Ratio	3.20	Sales past 5Y	29.40%	Gross Margin	72.50%	52W Low	249.63%	ATR	0.90
Employees	182	Current Ratio	3.50	Sales Q/Q	21.90%	Oper. Margin	2.10%	RSI (14)	77.38	Volatility	7.16% 5.09%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	23.10%	Profit Margin	-25.50%	Rel Volume	1.89	Prev Close	19.13
Shortable	Yes	LT Debt/Eq	60.17	Earnings	Nov 14 AMC	Payout	-	Avg Volume	243.30K	Price	18.88
Recom	1.70	SMA20	26.37%	SMA50	39.10%	SMA200	92.94%	Volume	259,957	Change	-1.31%

Sep-08-22

Resumed

B. Riley Securities

Buy

$17

Oct-14-21

Resumed

B. Riley Securities

Buy

$16

Sep-24-21

Initiated

Aegis Capital

Buy

$15

Jul-02-21

Initiated

Ladenburg Thalmann

Buy

$14.25

Feb-03-23 08:50AM	Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable Zacks +8.29%
Feb-02-23 06:30AM	Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023 Business Wire +6.53%
Jan-23-23 07:00AM	Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products Business Wire
Jan-21-23 07:33AM	Investing in Harrow Health (NASDAQ:HROW) five years ago would have delivered you a 752% gain Simply Wall St.
Jan-18-23 08:50AM	Recent Price Trend in Harrow (HROW) is Your Friend, Here's Why Zacks
07:00AM	Loading…
Jan-05-23 07:00AM	Harrow Announces Availability of Fortisite Formulations for In-Office Use Business Wire
Dec-25-22 07:24AM	Trade Alert: The CEO & Chairman of the Board Of Harrow Health, Inc. (NASDAQ:HROW), Mark Baum, Has Just Spent US$335k Buying 1.8% More Shares Simply Wall St.
Dec-21-22 09:21AM	Melt Pharmaceuticals MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study Business Wire +10.57%
Dec-16-22 07:00AM	Harrow Secures Capital to Close Recently Announced Acquisition Business Wire
Dec-14-22 03:24PM	Harrow Health inks $175 million deal for the rights to five medications American City Business Journals +15.05%
09:41AM	Harrow Health Acquires Rights To Novartis' Five Approved Ophthalmic Products Benzinga
06:32AM	Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and "BB" Rating from Egan-Jones Business Wire
06:31AM	Harrow Prices $25 Million Offering Business Wire
06:30AM	Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® Business Wire
Nov-30-22 08:00AM	Harrow and iOR Partners Expand National Product Supply Agreement Business Wire
05:06AM	Loading…
Nov-16-22 05:06AM	Harrow Health Third Quarter 2022 Earnings: Misses Expectations Simply Wall St. -5.60%
Nov-14-22 04:05PM	Harrow Announces Third Quarter 2022 Financial Results Business Wire
Nov-10-22 08:00AM	Harrow Launches Atropine.com Business Wire
Oct-28-22 08:00AM	Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022 Business Wire
Oct-27-22 08:00AM	Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300 Business Wire
Oct-13-22 09:35AM	Harrow Health, Inc. (NASDAQ:HROW) has caught the attention of institutional investors who hold a sizeable 48% stake Simply Wall St.
Oct-06-22 03:23PM	Harrow Health sells part of company for up to $10.5 million American City Business Journals
Oct-05-22 05:35PM	Harrow Sells Non-Ophthalmic Compounding Business Business Wire
Sep-29-22 07:00AM	ImprimisRx Launches Fortisite (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation Business Wire +16.25%
Sep-28-22 07:09AM	FDA Approves First Branded Ocular Anesthetic In Almost 14 Years Benzinga
Sep-27-22 01:50PM	Harrow Announces U.S. FDA Approval of IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Business Wire +27.86%
Sep-21-22 06:01PM	Melt Pharmaceuticals files for IPO MarketWatch
Aug-27-22 06:37PM	Is Harrow Health (HROW) a Wise Investment Choice? Insider Monkey
Aug-11-22 08:00AM	Harrow Health to Participate in H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference Business Wire +11.63%
Aug-09-22 04:45PM	Edited Transcript of HROW.OQ earnings conference call or presentation 9-Aug-22 8:45pm GMT Thomson Reuters StreetEvents
04:01PM	Loading…
04:01PM	Harrow Health Announces Second Quarter 2022 Financial Results Business Wire
Jul-27-22 07:00AM	Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022 Business Wire
Jul-16-22 08:08AM	Harrow Health's (NASDAQ:HROW) investors will be pleased with their stellar 151% return over the last five years Simply Wall St.
Jun-24-22 08:00AM	Harrow Health Announces Launch of IOPIDINE® 1% and MAXITROL® in the United States Business Wire +10.30%
May-30-22 06:12AM	7 Mighty Micro-Cap Stocks That Could Be Future Moonshots InvestorPlace
May-06-22 09:01AM	Is Harrow Health, Inc.'s (NASDAQ:HROW) Shareholder Ownership Skewed Towards Insiders? Simply Wall St. +6.39%
May-05-22 04:01PM	Harrow Health Announces First Quarter 2022 Financial Results Business Wire
May-04-22 08:00AM	Melt Pharmaceuticals Announces MELT-210 Top-Line Results of Phase 1 Pharmacokinetics (PK) Study for Procedural Sedation Business Wire
Apr-22-22 08:00AM	Harrow Health to Participate in B. Riley Securities Annual Neuro & Ophthalmology Investor Conference Business Wire
Apr-20-22 07:00AM	Harrow Health to Announce First Quarter 2022 Financial Results on May 5, 2022 Business Wire
Mar-31-22 07:00AM	Harrow Health Announces Appointments to Its Board of Directors Business Wire
Mar-10-22 04:01PM	Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results Business Wire
08:00AM	Melt Pharmaceuticals Names Experienced Executive Brad Osborne as Chief Financial Officer Business Wire
Feb-24-22 08:00AM	Harrow Health to Announce Fourth Quarter and Year-End 2021 Financial Results on March 10, 2022 Business Wire
Feb-22-22 07:00AM	Harrow Health Announces FDA Acceptance of New Drug Application for AMP-100 Business Wire +5.34%
Feb-15-22 07:00AM	Harrow Health to Present at Aegis Virtual Conference Business Wire
Feb-10-22 04:50PM	Two Insider Moonshots Rising on Sudden Buying InvestorPlace
Feb-08-22 08:00AM	Harrow Health Publishes Corporate Transparency Report Business Wire
Feb-06-22 08:36AM	Harrow Health (NASDAQ:HROW) swells 13% this week, taking five-year gains to 236% Simply Wall St.
Jan-10-22 06:45AM	Harrow Health to Participate in H.C. Wainwright BioConnect Conference Business Wire
Jan-04-22 08:00AM	Melt Pharmaceuticals Submits INDs for MELT210 and MELT-400 to FDA Business Wire -5.89%
Dec-30-21 10:24AM	Select Medical's (SEM) Rising Stake in Concentra to Aid Zacks
Dec-20-21 07:00AM	Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops Business Wire
Dec-13-21 08:00AM	Harrow Health Added to the Nasdaq Biotechnology Index Business Wire
Dec-07-21 04:32PM	EyePoint Pharmaceuticals and Harrow Healths ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU® GlobeNewswire
Dec-06-21 11:54AM	Why Seasoned Investors are Retaining Select Medical (SEM) Stock Zacks
Nov-29-21 10:00AM	Harrow (HROW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? Zacks
Nov-19-21 12:20PM	Earnings Estimates Moving Higher for Harrow (HROW): Time to Buy? Zacks
Nov-09-21 06:25PM	Harrow Health (HROW) Beats Q3 Earnings and Revenue Estimates Zacks
04:01PM	Harrow Health Announces Third Quarter 2021 Financial Results Business Wire
Nov-07-21 08:53AM	These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Reasonably Well Simply Wall St.
Oct-25-21 09:00AM	Harrow Health to Announce Third Quarter 2021 Financial Results on November 9, 2021 Business Wire
Sep-27-21 08:26AM	Here's What Harrow Health, Inc.'s (NASDAQ:HROW) Shareholder Ownership Structure Looks Like Simply Wall St.
Sep-02-21 08:00AM	Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals Business Wire
Aug-18-21 07:00AM	Harrow Health Acquires Ophthalmic Surgical Drug Candidate From Wakamoto Pharmaceutical Co., Ltd. Business Wire
Aug-13-21 01:21AM	Harrow Health, Inc. (NASDAQ:HROW) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates Simply Wall St.
Aug-12-21 12:45PM	SRK Capital: Harrow Health (HROW) is Potentially Worth Multiples of its Current Valuation Insider Monkey
07:45AM	Harrow Health to Participate in Two Upcoming Virtual Investor Conferences Business Wire
Aug-10-21 05:15PM	Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	Harrow Health Announces Second Quarter 2021 Financial Results Business Wire
Aug-05-21 10:57AM	What's in Store for Harrow Health (HROW) in Q2 Earnings? Zacks
Aug-03-21 03:01PM	Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for Zacks
05:07AM	Introducing Harrow Health (NASDAQ:HROW), The Stock That Zoomed 265% In The Last Three Years Simply Wall St.
Aug-02-21 05:50PM	Harrow Health (HROW) Gains As Market Dips: What You Should Know Zacks
Jul-28-21 11:30AM	Is Harrow Health (HROW) Stock Outpacing Its Medical Peers This Year? Zacks
Jul-27-21 07:00AM	Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica Business Wire
Jul-26-21 09:00AM	Harrow Health to Announce Second Quarter 2021 Financial Results on August 10, 2021 GlobeNewswire
Jul-19-21 08:00AM	NovaBay Pharmaceuticals Partners with Harrow Healths ImprimisRx® to Promote Prescription Avenova Business Wire
Jul-16-21 10:00AM	Down 14% in 4 Weeks, Here's Why You Should You Buy the Dip in Harrow (HROW) Zacks
Jul-15-21 08:00AM	Harrow Health Granted Two Patents for Novel Surgical Dilation Formulation GlobeNewswire
Jul-06-21 08:27AM	Bet on 4 Low-Beta MedTech Stocks to Ride the Choppy Market Zacks -6.30%
Jun-23-21 06:34AM	Harrow (HROW) Surges 12%: Is This an Indication of Further Gains? Zacks +6.02%
Jun-17-21 04:01PM	Harrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026 GlobeNewswire
Jun-14-21 05:59PM	Harrow Health Announces Pricing of $17.5 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026 GlobeNewswire
07:45AM	Harrow Health Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and BB Rating from Egan-Jones GlobeNewswire
Jun-04-21 04:03AM	Is Harrow Health, Inc.'s(NASDAQ:HROW) Recent Stock Performance Tethered To Its Strong Fundamentals? Simply Wall St.
Jun-03-21 08:15AM	Visionology Acquires Exclusive Worldwide License to SPARCS Contrast Sensitivity Testing Technology GlobeNewswire
Jun-01-21 09:00AM	Harrow Health Launches New Corporate and Investor Website GlobeNewswire
May-17-21 09:00AM	Leading Peer-Reviewed Ophthalmic Journal Publishes Study on ImprimisRxs Proprietary Klarity-C® Drops GlobeNewswire
May-11-21 04:01PM	Harrow Health Announces Record First Quarter 2021 Financial Results GlobeNewswire
02:45PM	Harrow Health, Inc. to Host Earnings Call ACCESSWIRE
May-05-21 04:03PM	Harrow Health Raises Approximately $11 Million in Sale of Series B Preferred Stock GlobeNewswire
04:01PM	Harrow Health Announces Full Exercise and Closing of Option to Purchase Additional Senior Notes GlobeNewswire
May-04-21 03:00PM	Will Harrow Health (HROW) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-27-21 09:00AM	Harrow Health to Announce First Quarter 2021 Financial Results on May 11, 2021 GlobeNewswire
Apr-20-21 04:01PM	Harrow Health Announces Closing of $50 Million Offering of Senior Notes Due 2026 GlobeNewswire
Apr-15-21 05:00PM	Harrow Health Announces Pricing of $50 Million Offering of Senior Notes Due 2026 GlobeNewswire +8.31%
Apr-14-21 04:01PM	Harrow Health Announces Offering of $25 Million Senior Notes Due 2026 and BB Rating from Egan-Jones GlobeNewswire
04:00PM	Harrow Health Announces Preliminary First Quarter 2021 Financial Results GlobeNewswire
Apr-05-21 05:43AM	Do Insiders Own Lots Of Shares In Harrow Health, Inc. (NASDAQ:HROW)? Simply Wall St.

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BOLL ANDREW R.	Chief Financial Officer	Dec 22	Buy	13.54	2,500	33,850	255,063	Dec 23 07:02 AM
BAUM MARK L	Chief Executive Officer	Dec 22	Buy	13.39	25,000	334,750	1,432,141	Dec 23 07:03 AM
Van Horn R. Lawrence	Director	Dec 22	Buy	13.42	1,860	24,961	1,860	Dec 23 07:00 AM
Makary Martin A.	Director	Dec 21	Buy	13.37	25,000	334,250	25,000	Dec 23 07:01 AM
Opaleye Management Inc.	10% Owner	Dec 14	Buy	10.52	431,183	4,536,045	3,600,000	Dec 14 04:05 PM
LINDSTROM RICHARD L MD	Director	Sep 30	Sale	12.62	40,000	504,800	26,100	Oct 03 06:02 PM
Opaleye Management Inc.	10% Owner	Sep 28	Buy	9.77	11,085	108,354	3,185,000	Sep 30 06:15 AM
Opaleye Management Inc.	10% Owner	Apr 13	Buy	6.76	12,832	86,785	3,175,000	Apr 13 06:33 PM
Opaleye Management Inc.	10% Owner	Apr 12	Buy	6.75	28,557	192,717	3,165,000	Apr 13 06:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience